September 01, 2025

Use of Trigger Point Injections in the Management of Myofascial Pain in Patients With Temporomandibular Disorders

The case underscores the importance of accurate diagnosis and multidisciplinary management of myofascial pain, highlighting TPI therapy as an effective, minimally invasive treatment within a multimodal care approach.

Compendium

August 22, 2025

Patient Awareness of Pharmacogenomic Testing Remains Low, ACS CAN Survey Reports

Less than half of responding patients with cancer were previously familiar with pharmacogenomic testing and its possible benefits, according to the results of a survey conducted by the American Cancer...

The ASCO Post

August 22, 2025

New Recommendations Released for Managing Aromatase Inhibitor–Induced Bone Loss

A group of experts from seven professional societies have published a joint position statement in the Journal of Bone Oncology on the management of aromatase inhibitor–associated bone loss as a guide ...

The ASCO Post

August 22, 2025

Nivolumab Plus Ipilimumab in mCRPC With an Immunogenic Signature

In a UK phase II trial (NEPTUNES) reported in the Journal of Clinical Oncology, Leone et al evaluated the efficacy of nivolumab plus ipilimumab in previously treated patients with immunogenic signatur...

The ASCO Post

August 22, 2025

Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

In a phase II study (ENGOT-OV60/GOG-3052/RAMP 201) reported in the Journal of Clinical Oncology, Banerjee et al evaluated the efficacy and safety of the RAF/MEK clamp avutometinib in combination with ...

The ASCO Post

August 15, 2025

Mount Sinai Neurosurgeon Leads Development of First CNS Guidelines for Treating Functioning Pituitary Adenomas

The Congress of Neurological Surgeons (CNS) has released its first comprehensive, evidence-based guidelines for the care of adults with functioning pituitary adenomas (FPAs), a common yet complex condition.

Mount Sinai New York

August 15, 2025

The Inflation Reduction Act and Ibrutinib

In August 2024, the Centers for Medicare & Medicaid Services (CMS) announced a negotiated price for the Bruton’s tyrosine kinase inhibitor ibrutinib that is 38% lower than the manufacturer’s list ...

The ASCO Post

August 14, 2025

Cannabis Use Disorder and Risk of Oral Cancer

Cannabis use disorder was associated with at least a threefold increase in the risk for developing oral cancer over 5 years compared with those without cannabis use disorder, according to findings fro...

The ASCO Post

August 13, 2025

Ozempic and Vision

Understanding recent updates to the risks associated with semaglutide

The Ophthalmologist